Takeda Pharmaceutical Company Limited (TAK)
$15.61
$-0.17
(-1.05%)
As on 16-Jun-2026 14:46EDT
Market cap
$50,144 Mln
Revenue (TTM)
$4,547,341 Mln
P/E Ratio
42.9
P/B Ratio
1
Div. Yield
4.2 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$216,081 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
9.2
-
Debt to Equity
0.6
-
Book Value
$2498.4
-
EPS
$65.1
-
Face value
--
-
Shares outstanding
3,159,673,660
10 Years Aggregate
CFO
$5,104,983.00 Mln
EBITDA
$6,224,538.00 Mln
Net Profit
$1,419,323.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Takeda Pharmaceutical Company Limited (TAK)
| 0.1 | -6.1 | -12.2 | 2.7 | -1.1 | -1.9 | -2.9 |
|
BSE Sensex
| -9.3 | 2.1 | 3.0 | -5.3 | 6.9 | 7.8 | 11.1 |
|
S&P Midcap 400
| 13.6 | 5.3 | 13.8 | 26.4 | 13.6 | 6.9 | 9.9 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Takeda Pharmaceutical Company Limited (TAK)
| 17.7 | -7.2 | -8.5 | 14.5 | -25.1 | -7.8 | 17.3 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Takeda Pharmaceutical Company Limited (TAK)
|
15.6 | 50,144.0 | 4,777,450.3 | 203,326.8 | 13.7 | 2.8 | 42.9 | 1.0 |
| 222.0 | 397,122.0 | 62,819.0 | 3,639.0 | 14.1 | -- | 109.6 | 50.5 | |
| 347.9 | 191,704.4 | 37,238.0 | 7,800.0 | 31.7 | 82.9 | 24.7 | 20.9 | |
| 1,126.7 | 1,035,267.1 | 72,249.5 | 25,275.0 | 44.1 | 91.9 | 41.3 | 32.5 | |
| 126.5 | 155,928.8 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.1 | 6.6 | |
| 234.5 | 579,826.4 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 27.9 | 7.1 | |
| 115.0 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 151.0 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.0 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 33.0 | 40,242.6 | 17,348.0 | 1,564.0 | 13.1 | 20.2 | 25.8 | 4.9 |
Shareholding Pattern
View DetailsAbout Takeda Pharmaceutical Company Limited (TAK)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare... diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan. Read more
-
President, CEO & Representative Director
Mr. Christophe Weber
-
Chair of Management Board
Dr. Seigo Izumo
-
Headquarters
Tokyo
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Takeda Pharmaceutical Company Limited (TAK)
What is the current share price of Takeda Pharmaceutical Company Limited (TAK) Today?
The share price of Takeda Pharmaceutical Company Limited (TAK) is $15.61 (NYSE) as of 16-Jun-2026 14:46 EDT. Takeda Pharmaceutical Company Limited (TAK) has given a return of -1.14% in the last 3 years.
What is the current PB & PE ratio of Takeda Pharmaceutical Company Limited (TAK)?
The P/E ratio of Takeda Pharmaceutical Company Limited (TAK) is 42.89 times as on 12-Jun-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2026
|
0.28
|
0.01
|
|
2025
|
0.44
|
0.01
|
|
2024
|
0.30
|
0.01
|
|
2023
|
0.17
|
0.01
|
|
2022
|
0.20
|
0.01
|
What is the 52 Week High and Low of Takeda Pharmaceutical Company Limited (TAK)?
The 52-week high and low of Takeda Pharmaceutical Company Limited (TAK) are Rs 18.90 and Rs 12.99 as of 17-Jun-2026.
What is the market cap of Takeda Pharmaceutical Company Limited (TAK)?
Takeda Pharmaceutical Company Limited (TAK) has a market capitalisation of $ 50,144 Mln as on 12-Jun-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Takeda Pharmaceutical Company Limited (TAK)?
Before investing in Takeda Pharmaceutical Company Limited (TAK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.